WO2012029771A1 - 超音波感受性物質を含む腫瘍増殖抑制剤および腫瘍増殖抑制剤と低出力超音波を用いた腫瘍増殖抑制方法 - Google Patents
超音波感受性物質を含む腫瘍増殖抑制剤および腫瘍増殖抑制剤と低出力超音波を用いた腫瘍増殖抑制方法 Download PDFInfo
- Publication number
- WO2012029771A1 WO2012029771A1 PCT/JP2011/069590 JP2011069590W WO2012029771A1 WO 2012029771 A1 WO2012029771 A1 WO 2012029771A1 JP 2011069590 W JP2011069590 W JP 2011069590W WO 2012029771 A1 WO2012029771 A1 WO 2012029771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor growth
- substance
- tumor proliferation
- low
- ultrasonic
- Prior art date
Links
- 0 CC([C@@](CC*)C(N1)=CC(C(C*)=C2C)=NC2=C2)C1=CC(C([C@]1(C)O)=CC=*c(ccc(Cl)c3)c3Cl)=NC1=C[C@@]1NC2=C(C)C1C=C Chemical compound CC([C@@](CC*)C(N1)=CC(C(C*)=C2C)=NC2=C2)C1=CC(C([C@]1(C)O)=CC=*c(ccc(Cl)c3)c3Cl)=NC1=C[C@@]1NC2=C(C)C1C=C 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a tumor growth inhibitor containing an ultrasonic sensitive substance and a tumor growth inhibitory method using a tumor growth inhibitor and low-power ultrasound. More specifically, the present invention relates to a tumor growth inhibitor comprising an ultrasonic sensitive substance and an acoustic cavitation enhancement substance, and a tumor growth inhibiting method for inhibiting tumor growth by activating the tumor growth inhibitor with low-power ultrasound. In addition, the present invention relates to a low-power ultrasonic dynamic anticancer therapy using a combination of an ultrasonic sensitive substance and an acoustic cavitation enhancement substance.
- low-power ultrasound has the advantage of reaching deeper parts of the body than light, and is safer as seen from the fact that it is also used for fetal echo diagnosis. The effect of treatment cannot be expected.
- DDS gene therapy and drug delivery systems
- the present inventors investigated the action effect on cancer by the combined use of an ultrasonic sensitive substance that is activated by ultrasonic waves and hardly reacts to light and low output ultrasonic waves. It was. As a result, a very prominent effect (strong cytotoxic activity) was obtained in in vitro, but in the in vivo experimental system using cancer-bearing animals, it was expected from the results of in vitro. Such a strong tumor growth inhibitory effect was not recognized (Non-patent Document 3). This is probably because the ultrasound sensitive substance was not fully activated by low power ultrasound in the tumor tissue.
- the present inventors have intensively studied a method for sufficiently activating an ultrasonic sensitive substance in a tumor tissue in cancer therapy using low output ultrasonic waves.
- the ultrasonic sensitive substance is irradiated with low output ultrasonic waves.
- ultrasonic sensitivity is also achieved by ultrasound in an in vivo test system using cancer-bearing animals.
- the present invention was completed by finding that the substance was sufficiently activated to obtain a significant tumor growth inhibitory effect.
- an object of the present invention is to provide a tumor growth inhibitor containing, as one form, an ultrasonic sensitive substance and an acoustic cavitation phenomenon enhancing substance.
- the present invention relates to a method for inhibiting tumor growth, comprising suppressing tumor growth by irradiating a tumor growth inhibitor comprising an ultrasonic sensitive substance and an acoustic cavitation phenomenon enhancing substance with low-power ultrasound.
- the purpose is to provide.
- the present invention provides, as one form, a tumor growth inhibitor comprising an ultrasonic sensitive substance and an acoustic cavitation enhancing substance.
- the present invention provides a tumor growth inhibitor, wherein the ultrasonic sensitive substance is a porphyrin derivative or a xanthene derivative.
- porphyrin derivative is represented by the formula [I]:
- a tumor growth inhibitor comprising methylchlorin disodium salt.
- a tumor growth inhibitor wherein the acoustic cavitation enhancing substance is a gas-filled bubble (bubble), for example, a microbubble or a nanobubble, which causes an acoustic cavitation phenomenon with low-power ultrasonic waves.
- a gas-filled bubble for example, a microbubble or a nanobubble
- This invention provides, as another further preferred embodiment, a tumor growth inhibitor wherein the acoustic cavitation enhancing substance is sonazoid or levovist.
- the present invention provides a method for inhibiting tumor growth, which comprises suppressing tumor growth by irradiating a tumor growth inhibitor containing an ultrasonic sensitive substance and an acoustic cavitation enhancing substance with low-power ultrasound. To do.
- the present invention provides a method for inhibiting tumor growth, wherein the ultrasonic sensitive substance is a porphyrin derivative or a xanthene derivative.
- porphyrin derivative is represented by the formula [I]:
- the present invention provides a method for inhibiting tumor growth, wherein the acoustic cavitation enhancing substance is a bubble (such as a bubble) that causes an acoustic cavitation phenomenon with low-power ultrasound, for example, a microbubble or a nanobubble. .
- the acoustic cavitation enhancing substance is a bubble (such as a bubble) that causes an acoustic cavitation phenomenon with low-power ultrasound, for example, a microbubble or a nanobubble.
- the present invention provides a method for inhibiting tumor growth, wherein the substance for enhancing acoustic cavitation phenomenon is sonazoid or levovist.
- This invention provides, as yet another preferred embodiment, a method for inhibiting tumor growth, wherein low-power ultrasound induces an acoustic cavitation phenomenon and excites an ultrasound-sensitive substance.
- an ultrasonic sensitive substance can be activated by the use of low-power ultrasonic waves that are used for echo diagnosis, and the tumor damaging activity can be remarkably enhanced in vivo. have.
- the figure which shows the comparative effect of the case where ultrasonic treatment is carried out after administration of DEG and sonazoid, and the case of non-treatment (Example 1).
- the figure which shows the comparative effect of the case of ultrasonic treatment after administration of DEG alone and the case of non-treatment (Comparative Example 1).
- mouth after intratumor administration, immediately after ultrasonic treatment, 1 week, and 3 weeks later (Example 1).
- part (subcutaneous tumor) of a cancer-bearing mouse with time (Example 2).
- mouth (Example 2).
- the present invention provides, as one form, a tumor growth inhibitor comprising an ultrasonic sensitive substance and an acoustic cavitation enhancing substance.
- the tumor growth inhibitor according to the present invention has an effect of suppressing the growth of a tumor in a living body by irradiating a low-power ultrasonic wave to enhance the acoustic cavitation phenomenon of the acoustic cavitation phenomenon-enhancing substance to excite the ultrasonic sensitive substance. is there.
- any substance can be used as long as it is activated by irradiation with low-power ultrasonic waves and can exert a tumor growth inhibitory effect.
- a porphyrin derivative or a xanthene derivative can be given as an example.
- porphyrin derivatives for example, the formula [I]:
- the ultrasonic sensitive substance used in the present invention means a substance that does not substantially react to light, that is, hardly reacts to light or does not react completely, but reacts to ultrasound.
- examples of the acoustic cavitation enhancing substance that can be used in the present invention include gas-filled bubbles such as nanobubbles and microbubbles. Specific examples thereof include sonazoid and levovist.
- the low-power ultrasound used in the method for inhibiting tumor growth of the present invention is not particularly limited as long as it is a low-power ultrasound capable of activating the tumor growth inhibitor of the present invention.
- the ultrasonic wave is preferably in the range of 0.1 to 10.0 W / cm 2 and about 0.1 to 5.0 MHz.
- the MI value is preferably an ultrasonic wave of less than 2.
- the recommended value for sonazoid angiography is between 0.2 and 0.3 as the MI value.
- the tumor growth inhibitor according to the present invention is formulated by conventional means commonly used in the art in combination with a preparation carrier suitable for an administration form, in addition to an ultrasonic sensitive substance and an acoustic cavitation enhancing substance. It is good to do.
- the dosage form is not particularly limited and can be administered orally or parenterally, and is administered in a dosage form suitable for the dosage form.
- orally administrable dosage forms include tablets such as sugar-coated tablets and film coating agents, and oral agents such as capsules, granules, emulsions, powders, emulsions, suspensions and syrups.
- Examples of dosage forms that can be administered parenterally include injections such as subcutaneous, intravenous, intramuscular, intraperitoneal, and parenteral agents such as infusions.
- parenteral agents such as infusions.
- the shape of the ultrasonic sensitive substance itself is not particularly limited as long as it is suitable for the dosage form.
- the shape is powdery, particulate (including nanoparticulate) or liquid. It may be.
- Examples of the pharmaceutical carrier that can be used to formulate the tumor growth inhibitor of the present invention include, for example, calcium carbonate, kaolin, sodium hydrogen carbonate, lactose, starches, crystalline cellulose, talc, granulated sugar, and the like, dextrin , Rubber, alcoholic starch, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, pullulan and other binders, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, partially pregelatinized starch, etc.
- lubricants such as magnesium stearate, calcium stearate, talc, starch, sodium benzoate, coloring agents such as tar pigments, caramel, iron sesquioxide, titanium oxide, riboflavin, sweeteners, flavoring agents such as fragrances, Sulfurous acid Stabilizers such as sodium, parabens, such as preservatives, such as sorbic acid.
- the tumor growth inhibitor of the present invention can also be administered in combination with other drugs, particularly anticancer agents.
- the administration method may be a method in which other pharmaceuticals are also included in the preparation of the tumor growth inhibitor, or a method in which the tumor growth inhibitor and other pharmaceuticals are administered separately.
- the dose of the tumor growth inhibitor of the present invention can be appropriately changed depending on the administration route, symptoms, patient age, body weight, etc., ultrasonic irradiation dose, irradiation time, and the like.
- the dosage is not particularly limited as long as the effective concentration of the ultrasonic sensitive substance in the tumor growth inhibitor is an amount that can be retained in the body during the irradiation time of the ultrasonic wave. It is better to change as appropriate.
- the irradiation amount and irradiation time of the low-power ultrasonic wave in this invention may be appropriately changed according to the dosage of the tumor growth inhibitor, the administration route, the symptom, the age of the patient, the body weight, and the like.
- Example 1 In substantially the same manner as in Example 1, ultrasonic treatment was performed using DEG alone. The result is shown in FIG. 2 as a comparative example.
- This example shows a cancer suppressing effect at a specific site (subcutaneous tumor).
- ultrasonic sensitive substance DEG 5 ⁇ M
- ultrasonic sensitizer sonazoid Sonitron 1000
- Sonitron 1000 10 minutes under the conditions of 1 W / cm 2 , 1 MHz, 50% duty cycle .
- Ultrasonic irradiation was performed 3 times every other day (arrows in FIG. 4, ⁇ ), and the size of the tumor was measured.
- this invention can exhibit an antitumor effect by using an ultrasonic sensitive substance and an acoustic cavitation phenomenon-enhancing substance in combination, and using an ultrasonic wave with low output that is used for echo diagnosis, Compared with photodynamic therapy using a photosensitive substance, the patient's QOL can be significantly improved. Therefore, this invention can be expected to develop a new minimally invasive cancer treatment using low-power ultrasound in cancer treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
実施例1と実質的に同様にして、DEG単独を用いて超音波処置を行った。その結果を比較例として図2に示す。
Claims (13)
- 超音波感受性物質と音響キャビテーション現象増強物質とを含むことを特徴とする腫瘍増殖抑制剤。
- 請求項1に記載の腫瘍増殖抑制剤であって、前記超音波感受性物質が、ポルフィリン誘導体またはキサンテン誘導体であることを特徴とする腫瘍増殖抑制剤。
- 請求項1に記載の腫瘍増殖抑制剤であって、前記音響キャビテーション現象増強物質が、ガス封入バブル(気泡)であることを特徴とする腫瘍増殖抑制剤。
- 請求項4に記載の腫瘍増殖抑制剤であって、前記ガス封入バブルが、マイクロバブルまたはナノバブルであることを特徴とする腫瘍増殖抑制剤。
- 請求項5に記載の腫瘍増殖抑制剤であって、前記ガス封入バブルが、ソナゾイド(sonazoid)またはレボビスト(levovist)であることを特徴とする腫瘍増殖抑制剤。
- 超音波感受性物質と音響キャビテーション現象増強物質とを含む腫瘍増殖抑制剤に低出力超音波を照射することによって腫瘍増殖を抑制することを特徴とする腫瘍増殖抑制方法。
- 請求項7に記載の腫瘍増殖抑制方法であって、前記超音波感受性物質が、ポルフィリン誘導体またはキサンテン誘導体であることを特徴とする腫瘍増殖抑制方法。
- 請求項7に記載の腫瘍増殖抑制方法であって、前記音響キャビテーション現象増強物質が、低出力超音波で音響キャビテーション現象を惹起するガス封入バブル(気泡)であることを特徴とする腫瘍増殖抑制方法。
- 請求項10に記載の腫瘍増殖抑制方法であって、前記ガス封入バブルが、マイクロバブルまたはナノバブルであることを特徴とする腫瘍増殖抑制方法。
- 請求項10または11に記載の腫瘍増殖抑制方法であって、前記ガス封入バブルがソナゾイド(sonazoid)またはレボビスト(levovist)であることを特徴とする腫瘍増殖抑制方法。
- 請求項7に記載の腫瘍増殖抑制方法であって、前記低出力超音波が、音響キャビテーション現象を惹起し超音波感受性物質を励起するものであることを特徴とする腫瘍増殖抑制方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/812,922 US20130129799A1 (en) | 2010-08-30 | 2011-08-30 | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves |
JP2012531890A JP5908839B2 (ja) | 2010-08-30 | 2011-08-30 | 超音波感受性物質を含む腫瘍増殖抑制剤および腫瘍増殖抑制剤と低出力超音波を用いた腫瘍増殖抑制方法 |
US14/186,859 US9764029B2 (en) | 2010-08-30 | 2014-02-21 | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-192916 | 2010-08-30 | ||
JP2010192916 | 2010-08-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/812,922 A-371-Of-International US20130129799A1 (en) | 2010-08-30 | 2011-08-30 | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves |
US14/186,859 Division US9764029B2 (en) | 2010-08-30 | 2014-02-21 | Tumor proliferation inhibitor containing ultrasound-sensitive substance and method for inhibiting tumor proliferation by using tumor proliferation inhibitor and low-intensity pulsed ultrasound waves |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012029771A1 true WO2012029771A1 (ja) | 2012-03-08 |
Family
ID=45772854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/069590 WO2012029771A1 (ja) | 2010-08-30 | 2011-08-30 | 超音波感受性物質を含む腫瘍増殖抑制剤および腫瘍増殖抑制剤と低出力超音波を用いた腫瘍増殖抑制方法 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20130129799A1 (ja) |
JP (1) | JP5908839B2 (ja) |
WO (1) | WO2012029771A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014047142A (ja) * | 2012-08-29 | 2014-03-17 | Fukuoka Univ | 水溶性チタニア・シリカ複合体を用いた薬剤 |
RU2581353C2 (ru) * | 2014-05-08 | 2016-04-20 | Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России | Способ лечения злокачественных новообразований кожи в проблемных зонах местной химиотерапией, усиленной близкофокусным ультразвуковым воздействием в адъювантном и неоадъювантном режимах |
WO2017056695A1 (ja) * | 2015-09-29 | 2017-04-06 | 株式会社日立製作所 | 細胞培養装置 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210213307A1 (en) * | 2013-03-06 | 2021-07-15 | B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Low intensity ultrasound therapy |
US10960233B2 (en) * | 2013-03-06 | 2021-03-30 | B.G. Negev Technologies And Applications Ltd. | Low intensity ultrasound therapy |
EP4349401A1 (en) | 2019-02-13 | 2024-04-10 | Alpheus Medical, Inc. | Non-invasive sonodynamic therapy |
-
2011
- 2011-08-30 US US13/812,922 patent/US20130129799A1/en not_active Abandoned
- 2011-08-30 WO PCT/JP2011/069590 patent/WO2012029771A1/ja active Application Filing
- 2011-08-30 JP JP2012531890A patent/JP5908839B2/ja active Active
-
2014
- 2014-02-21 US US14/186,859 patent/US9764029B2/en active Active
Non-Patent Citations (4)
Title |
---|
HIROFUMI TSURU ET AL.: "Atarashii Porphyrin Yudotai DEG-Mn-DP-H o Mochiita Gan no Choonpa Rikigaku Ryoho", JOURNAL OF MEDICAL ULTRASONICS, vol. 37, no. S468, 15 April 2010 (2010-04-15), pages 83-AP-001 * |
IWASE ET AL.: "Shinki Porphyrin Yudotai DCPH-P-Na(I) no Onkyo Kagakuteki Kasseika ni yoru Apoptosis Yudo", PHARMACOMETRICS, vol. 78, no. 5/6, 13 August 2010 (2010-08-13), pages 45 * |
KINOSHITA ET AL.: "Mechanism of Porphyrin-Induced Sonodynamic Effect: Possible Role of Hyperthermia", RADIATION RESEARCH, vol. 165, 2006, pages 299 - 306 * |
YANAGISAWA ET AL.: "PHAGOCYTOSIS OF ULTRASOUND CONTRASR AGENT MICROBUBBLES BY KUPFFER CELLS", ULTRASOUND IN MED.& BIOL., vol. 33, no. 2, 2007, pages 318 - 325 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014047142A (ja) * | 2012-08-29 | 2014-03-17 | Fukuoka Univ | 水溶性チタニア・シリカ複合体を用いた薬剤 |
RU2581353C2 (ru) * | 2014-05-08 | 2016-04-20 | Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России | Способ лечения злокачественных новообразований кожи в проблемных зонах местной химиотерапией, усиленной близкофокусным ультразвуковым воздействием в адъювантном и неоадъювантном режимах |
WO2017056695A1 (ja) * | 2015-09-29 | 2017-04-06 | 株式会社日立製作所 | 細胞培養装置 |
Also Published As
Publication number | Publication date |
---|---|
US20140287000A1 (en) | 2014-09-25 |
US9764029B2 (en) | 2017-09-19 |
JP5908839B2 (ja) | 2016-04-27 |
US20130129799A1 (en) | 2013-05-23 |
JPWO2012029771A1 (ja) | 2013-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5908839B2 (ja) | 超音波感受性物質を含む腫瘍増殖抑制剤および腫瘍増殖抑制剤と低出力超音波を用いた腫瘍増殖抑制方法 | |
Guo et al. | Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives | |
US20170007699A1 (en) | Sonosensitizer composition containing titanium oxide nanoparticle as active ingredient, composition for preventing or treating cancer comprising the same, and the preparation thereof | |
US20040068207A1 (en) | Active oxygen generator containing photosensitizer for ultrasonic therapy | |
Snipstad et al. | Sonopermeation enhances uptake and therapeutic effect of free and encapsulated cabazitaxel | |
CN105792847A (zh) | 急性骨髓性白血病(aml)的新型组合治疗 | |
Lu et al. | Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles | |
US11793983B2 (en) | Sonodynamic therapy using microbubbles and pulsed wave ultrasound methods and systems | |
Zahraie et al. | Simultaneous chemotherapy/sonodynamic therapy of the melanoma cancer cells using a gold-paclitaxel nanostructure | |
JP2007501239A (ja) | 放射線治療と組み合わせたvegfアンタゴニストの使用 | |
García et al. | Drug delivery using metal oxide nanoparticles | |
JP6462147B2 (ja) | Hsp90阻害ペプチド結合体及びその腫瘍治療における応用 | |
PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro | |
JP6418549B2 (ja) | 高密度焦点式超音波治療法と抗癌剤療法との併用療法に用いる抗癌剤 | |
EP2035020B1 (en) | Pharmaceutical composition for injectional, particularly targeted local administration | |
Huang et al. | Nanotechnology-enabled sonodynamic therapy against malignant tumors | |
JP2015518000A (ja) | 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法 | |
JP6695615B2 (ja) | Hifu治療装置 | |
ES2423944T3 (es) | Uso de acetato de megestrol para la mejora de la función cardiaca y el tratamiento de insuficiencia coronaria | |
JP6903318B2 (ja) | 一酸化窒素内包バブルリポソーム及びその利用 | |
US8318794B2 (en) | Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins | |
CN115919766B (zh) | 一种复合纳米胶束及其制备方法和应用 | |
US20230165972A1 (en) | Cancer therapy with microbubbles | |
JP2015091766A (ja) | 癌治療支援システム | |
RU2166945C1 (ru) | Радиосенсибилизирующее вещество для лечения онкологических заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11821787 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13812922 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2012531890 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11821787 Country of ref document: EP Kind code of ref document: A1 |